Biomerica Signs MSA for CDMO IVD Development; $1.75M Initial Target
AI Summary
Biomerica (BMRA) announced a Master Services Agreement with a confidential life‐sciences partner to develop proprietary in vitro diagnostic (IVD) assays, with an initial contract development target fee of over $1.75 million to be earned across multiple Statements of Work. All development will be performed at Biomerica's FDA‐licensed, ISO 13485‐certified facility using existing staff and equipment, with revenue recognized on milestone completion as deliverables are accepted, positioning the work as a capital‐light CDMO revenue stream while the company keeps its focus on inFoods® IBS. The $1.75M is an aggregate target across SOWs (not guaranteed revenue) and no revenue is recognized until individual SOWs are executed and milestones accepted; the partner's identity remains confidential.
Positives
- MSA provides initial contract development target of >$1.75M across multiple SOWs, giving near‑term revenue visibility
- Work to be done at FDA‑licensed, ISO 13485 facility using existing resources — expected to be capital‑light with operating leverage
- Biomerica won the engagement after a competitive evaluation, validating its CDMO assay development capabilities
Negatives
- No revenue will be recognized until individual SOWs are executed and milestone deliverables are accepted
- The $1.75M figure is an aggregate target across multiple SOWs and is not guaranteed
- Client identity is confidential, limiting visibility into counterparty strength and long‑term upside